Skip to main content

ADM Tronics Reports First Quarter of Fiscal Year 2021 Results

NORTHVALE, NJ / ACCESSWIRE / August 19, 2020 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2020 of Fiscal Year 2021.

ADM Tronics' first fiscal quarter ended June 30, 2020 encompassed a full three-month period impacted by the effects of the COVID-19 pandemic. ADMT took aggressive steps to minimize disruption of operations by securing Essential Manufacturer exemption from the statewide shutdown. This allowed continued research, development and manufacturing operations, throughout the quarter, while encompassing CDC safety guidelines. The Company established clerical activities remotely.

By maintaining full operational capability, ADMT's electronic segment manufacturing revenues increased over 86% to $288,062 for the quarter ended June 30, 2020 as compared to $154,767 for the same period last year. This was offset by revenues in engineering and chemical segments, combined, of $281,031 as compared to $676,054 for the same period last year, a decrease of 58%.

"Due to the pandemic, our first quarter was extremely challenging. Although many businesses shutdown or severely curtailed operations, we were steadfast in our efforts to persevere," stated Andre' DiMino, President of ADM Tronics. "That allowed us to increase our electronics segment revenue by over 86% compared to last year's first fiscal quarter. However, due directly to the effects of the pandemic on our customers, both our chemical and engineering segments posted reductions in revenues. Maintaining our commitment of advancing our proprietary developments, such as our Sonotron technology, we continued to invest in research and development. We are confident that, as the world emerges from this crisis, the investments made in our R&D, as well as our customers resuming demand for our products and services, we expect multiple avenues for substantial growth."

Revenues for the quarter ended June 30, 2020 were $569,093 as compared to $830,821 for the same period last year, a decrease of 31%. Net loss for June 30, 2020 was $115,736 as compared to net income of $52,769 for June 30, 2019. Complete financial results are available in the Company's Quarterly Report on Form 10Q for June 30, 2020, available at www.sec.gov.

Financial Highlights

   Three Months Ended     Three Months Ended  
   June 30, 2020    June 30, 2019 
Net Revenues  569,093    830,821 
                
Cost of Sales    401,503      396,009 
                
Gross Profit    167,590      434,812 
                
Operating expenses:               
Research and development    125,904      145,766 
Selling, general and administrative    219,780      214,255 
Depreciation and amortization    5,776      5,506 
                
Total operating Expenses    351,460      365,527 
                
Income (loss) from operations    (183,870)    69,285 
                
Total other income (expense)    13,634      5,484 
                
Income (loss) before provision for taxes    (170,236)    74,769 
                
Benefit (provision) for income taxes:               
Current    12,500      (1,000)
Deferred    42,000      (21,000)
                
Total benefit (provision) for income taxes    54,500      (22,000)
                
Net income (loss)  (115,736)   52,769 
                
Net income per common share  (0.00)   0.00 
Weighted average shares of common stock outstanding - diluted    67,588,504      67,588,504 
         

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, FDA-Registered medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact:
Andre' DiMino
201-767-6040 
andre@admtronics.com

SOURCE: ADM Tronics Unlimited, Inc.



View source version on accesswire.com:
https://www.accesswire.com/602502/ADM-Tronics-Reports-First-Quarter-of-Fiscal-Year-2021-Results

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.